European Commission Approval New Indications for Opdivo

Apr 6

Written By Team Rxtrospect

Click the link below to download pdf.doc.

Team Rxtrospect

TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SL; UKONIQ AA withdrawn from market

RxTROSPECT, Inc 2025 — All rights reserved. “RxTROSPECT” refers to RxTROSPECT, Inc.. RxTROSPECT, Inc. is an intelligence company offering a range of data and analytics products through its partnerships with Tableau, LLC (a subsidiary of Salesforce, Inc), and Mango Technologies, Inc. dba ClickUp.

Testimonials are specific to an individual Customer’s experience and may not be representative of all Customers. Unless otherwise indicated, Customers offering a Testimonial do not receive compensation and their statement does not present a conflict of interest.

RxTROSPECT is not affiliated with, sponsored, or endorsed by the companies listed, described, or featured on its site. Company logos or trademarks used do not imply endorsement and are the property of their respective owners.

This is a representative list of customers that work with RxTROSPECT as of January 1st, 2025. It is not known whether they approve or disapprove of our products.

European Commission Approval New Indications for Opdivo

TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SL; UKONIQ AA withdrawn from market

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

solutions

tools

ABOUT US

RESOURCES